nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS2—pancreatic cancer	0.517	1	CbGaD
Nabumetone—MPO—superior mesenteric artery—pancreatic cancer	0.0731	0.842	CbGeAlD
Nabumetone—CYP1A2—Dacarbazine—pancreatic cancer	0.0513	0.327	CbGbCtD
Nabumetone—CYP1A2—Tamoxifen—pancreatic cancer	0.0408	0.26	CbGbCtD
Nabumetone—CYP1A2—Erlotinib—pancreatic cancer	0.0347	0.221	CbGbCtD
Nabumetone—CYP1A2—Fluorouracil—pancreatic cancer	0.0301	0.192	CbGbCtD
Nabumetone—MPO—pancreas—pancreatic cancer	0.00264	0.0304	CbGeAlD
Nabumetone—PTGS2—gall bladder—pancreatic cancer	0.0026	0.0299	CbGeAlD
Nabumetone—MPO—digestive system—pancreatic cancer	0.00225	0.026	CbGeAlD
Nabumetone—PTGS2—islet of Langerhans—pancreatic cancer	0.0017	0.0196	CbGeAlD
Nabumetone—MPO—IL23-mediated signaling events—IL24—pancreatic cancer	0.00164	0.115	CbGpPWpGaD
Nabumetone—CYP1A2—digestive system—pancreatic cancer	0.00123	0.0142	CbGeAlD
Nabumetone—PTGS2—pancreas—pancreatic cancer	0.0012	0.0138	CbGeAlD
Nabumetone—PTGS1—digestive system—pancreatic cancer	0.00107	0.0123	CbGeAlD
Nabumetone—PTGS2—digestive system—pancreatic cancer	0.00102	0.0118	CbGeAlD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—GDI1—pancreatic cancer	0.000734	0.0515	CbGpPWpGaD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—pancreatic cancer	0.000508	0.0356	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—SOD2—pancreatic cancer	0.000344	0.0241	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—NFKBIA—pancreatic cancer	0.00034	0.0238	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—APOE—pancreatic cancer	0.000282	0.0198	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—SOD2—pancreatic cancer	0.00028	0.0196	CbGpPWpGaD
Nabumetone—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000262	0.00116	CcSEcCtD
Nabumetone—Paraesthesia—Gemcitabine—pancreatic cancer	0.000261	0.00116	CcSEcCtD
Nabumetone—Chills—Docetaxel—pancreatic cancer	0.000261	0.00116	CcSEcCtD
Nabumetone—Asthenia—Sunitinib—pancreatic cancer	0.00026	0.00115	CcSEcCtD
Nabumetone—Decreased appetite—Irinotecan—pancreatic cancer	0.00026	0.00115	CcSEcCtD
Nabumetone—Arrhythmia—Docetaxel—pancreatic cancer	0.00026	0.00115	CcSEcCtD
Nabumetone—Dyspnoea—Gemcitabine—pancreatic cancer	0.000259	0.00115	CcSEcCtD
Nabumetone—Insomnia—Fluorouracil—pancreatic cancer	0.000259	0.00115	CcSEcCtD
Nabumetone—Somnolence—Gemcitabine—pancreatic cancer	0.000259	0.00115	CcSEcCtD
Nabumetone—Hypokalaemia—Epirubicin—pancreatic cancer	0.000258	0.00114	CcSEcCtD
Nabumetone—Fatigue—Irinotecan—pancreatic cancer	0.000257	0.00114	CcSEcCtD
Nabumetone—Paraesthesia—Fluorouracil—pancreatic cancer	0.000257	0.00114	CcSEcCtD
Nabumetone—Alopecia—Docetaxel—pancreatic cancer	0.000257	0.00114	CcSEcCtD
Nabumetone—Pruritus—Sunitinib—pancreatic cancer	0.000257	0.00114	CcSEcCtD
Nabumetone—Constipation—Irinotecan—pancreatic cancer	0.000255	0.00113	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000255	0.00113	CcSEcCtD
Nabumetone—Dyspnoea—Fluorouracil—pancreatic cancer	0.000255	0.00113	CcSEcCtD
Nabumetone—Somnolence—Fluorouracil—pancreatic cancer	0.000254	0.00113	CcSEcCtD
Nabumetone—Decreased appetite—Gemcitabine—pancreatic cancer	0.000253	0.00112	CcSEcCtD
Nabumetone—Dyspepsia—Fluorouracil—pancreatic cancer	0.000252	0.00112	CcSEcCtD
Nabumetone—Nausea—Tamoxifen—pancreatic cancer	0.000251	0.00112	CcSEcCtD
Nabumetone—Fatigue—Gemcitabine—pancreatic cancer	0.000251	0.00111	CcSEcCtD
Nabumetone—Gastritis—Epirubicin—pancreatic cancer	0.000251	0.00111	CcSEcCtD
Nabumetone—Constipation—Gemcitabine—pancreatic cancer	0.000249	0.0011	CcSEcCtD
Nabumetone—Nausea—Erlotinib—pancreatic cancer	0.000249	0.0011	CcSEcCtD
Nabumetone—Decreased appetite—Fluorouracil—pancreatic cancer	0.000249	0.0011	CcSEcCtD
Nabumetone—Diarrhoea—Sunitinib—pancreatic cancer	0.000248	0.0011	CcSEcCtD
Nabumetone—Feeling abnormal—Irinotecan—pancreatic cancer	0.000246	0.00109	CcSEcCtD
Nabumetone—Dysphagia—Epirubicin—pancreatic cancer	0.000245	0.00109	CcSEcCtD
Nabumetone—Asthma—Epirubicin—pancreatic cancer	0.000245	0.00109	CcSEcCtD
Nabumetone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000244	0.00108	CcSEcCtD
Nabumetone—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000242	0.00107	CcSEcCtD
Nabumetone—Pancreatitis—Epirubicin—pancreatic cancer	0.00024	0.00107	CcSEcCtD
Nabumetone—Dizziness—Sunitinib—pancreatic cancer	0.00024	0.00106	CcSEcCtD
Nabumetone—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00024	0.00106	CcSEcCtD
Nabumetone—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000239	0.00106	CcSEcCtD
Nabumetone—Angina pectoris—Epirubicin—pancreatic cancer	0.000239	0.00106	CcSEcCtD
Nabumetone—Abdominal pain—Irinotecan—pancreatic cancer	0.000236	0.00105	CcSEcCtD
Nabumetone—Body temperature increased—Irinotecan—pancreatic cancer	0.000236	0.00105	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000236	0.00105	CcSEcCtD
Nabumetone—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000236	0.00105	CcSEcCtD
Nabumetone—Anaemia—Docetaxel—pancreatic cancer	0.000234	0.00104	CcSEcCtD
Nabumetone—Gastritis—Doxorubicin—pancreatic cancer	0.000232	0.00103	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—HES1—pancreatic cancer	0.000231	0.0162	CbGpPWpGaD
Nabumetone—Vomiting—Sunitinib—pancreatic cancer	0.000231	0.00102	CcSEcCtD
Nabumetone—Body temperature increased—Gemcitabine—pancreatic cancer	0.00023	0.00102	CcSEcCtD
Nabumetone—Dysuria—Epirubicin—pancreatic cancer	0.000229	0.00102	CcSEcCtD
Nabumetone—Rash—Sunitinib—pancreatic cancer	0.000229	0.00101	CcSEcCtD
Nabumetone—Dermatitis—Sunitinib—pancreatic cancer	0.000228	0.00101	CcSEcCtD
Nabumetone—Urticaria—Fluorouracil—pancreatic cancer	0.000227	0.00101	CcSEcCtD
Nabumetone—Headache—Sunitinib—pancreatic cancer	0.000227	0.00101	CcSEcCtD
Nabumetone—Syncope—Docetaxel—pancreatic cancer	0.000227	0.00101	CcSEcCtD
Nabumetone—Dysphagia—Doxorubicin—pancreatic cancer	0.000227	0.00101	CcSEcCtD
Nabumetone—Asthma—Doxorubicin—pancreatic cancer	0.000227	0.00101	CcSEcCtD
Nabumetone—Leukopenia—Docetaxel—pancreatic cancer	0.000226	0.00101	CcSEcCtD
Nabumetone—Body temperature increased—Fluorouracil—pancreatic cancer	0.000226	0.001	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—AHR—pancreatic cancer	0.000224	0.0157	CbGpPWpGaD
Nabumetone—Palpitations—Docetaxel—pancreatic cancer	0.000224	0.000992	CcSEcCtD
Nabumetone—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000224	0.000992	CcSEcCtD
Nabumetone—Weight increased—Epirubicin—pancreatic cancer	0.000223	0.000989	CcSEcCtD
Nabumetone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—pancreatic cancer	0.000223	0.0156	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—SOD2—pancreatic cancer	0.000222	0.0156	CbGpPWpGaD
Nabumetone—Loss of consciousness—Docetaxel—pancreatic cancer	0.000222	0.000987	CcSEcCtD
Nabumetone—Pancreatitis—Doxorubicin—pancreatic cancer	0.000222	0.000986	CcSEcCtD
Nabumetone—Weight decreased—Epirubicin—pancreatic cancer	0.000222	0.000983	CcSEcCtD
Nabumetone—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000221	0.000981	CcSEcCtD
Nabumetone—Cough—Docetaxel—pancreatic cancer	0.000221	0.00098	CcSEcCtD
Nabumetone—Angina pectoris—Doxorubicin—pancreatic cancer	0.000221	0.00098	CcSEcCtD
Nabumetone—Hypersensitivity—Irinotecan—pancreatic cancer	0.00022	0.000977	CcSEcCtD
Nabumetone—Pneumonia—Epirubicin—pancreatic cancer	0.00022	0.000975	CcSEcCtD
Nabumetone—Hypertension—Docetaxel—pancreatic cancer	0.000218	0.00097	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—pancreatic cancer	0.000218	0.0153	CbGpPWpGaD
Nabumetone—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000216	0.000961	CcSEcCtD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—pancreatic cancer	0.000216	0.0151	CbGpPWpGaD
Nabumetone—Nausea—Sunitinib—pancreatic cancer	0.000215	0.000956	CcSEcCtD
Nabumetone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS1—pancreatic cancer	0.000215	0.0151	CbGpPWpGaD
Nabumetone—Renal failure—Epirubicin—pancreatic cancer	0.000215	0.000953	CcSEcCtD
Nabumetone—Asthenia—Irinotecan—pancreatic cancer	0.000214	0.000951	CcSEcCtD
Nabumetone—Jaundice—Epirubicin—pancreatic cancer	0.000213	0.000945	CcSEcCtD
Nabumetone—Stomatitis—Epirubicin—pancreatic cancer	0.000213	0.000945	CcSEcCtD
Nabumetone—Dysuria—Doxorubicin—pancreatic cancer	0.000212	0.000941	CcSEcCtD
Nabumetone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000211	0.000936	CcSEcCtD
Nabumetone—Dry mouth—Docetaxel—pancreatic cancer	0.000211	0.000935	CcSEcCtD
Nabumetone—Asthenia—Gemcitabine—pancreatic cancer	0.000209	0.000927	CcSEcCtD
Nabumetone—Haematuria—Epirubicin—pancreatic cancer	0.000208	0.000924	CcSEcCtD
Nabumetone—Confusional state—Docetaxel—pancreatic cancer	0.000208	0.000924	CcSEcCtD
Nabumetone—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000207	0.000918	CcSEcCtD
Nabumetone—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000206	0.000917	CcSEcCtD
Nabumetone—Oedema—Docetaxel—pancreatic cancer	0.000206	0.000917	CcSEcCtD
Nabumetone—Weight increased—Doxorubicin—pancreatic cancer	0.000206	0.000915	CcSEcCtD
Nabumetone—Pruritus—Gemcitabine—pancreatic cancer	0.000206	0.000914	CcSEcCtD
Nabumetone—Weight decreased—Doxorubicin—pancreatic cancer	0.000205	0.00091	CcSEcCtD
Nabumetone—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000204	0.000907	CcSEcCtD
Nabumetone—Diarrhoea—Irinotecan—pancreatic cancer	0.000204	0.000907	CcSEcCtD
Nabumetone—Agranulocytosis—Epirubicin—pancreatic cancer	0.000204	0.000905	CcSEcCtD
Nabumetone—Pneumonia—Doxorubicin—pancreatic cancer	0.000203	0.000902	CcSEcCtD
Nabumetone—Shock—Docetaxel—pancreatic cancer	0.000203	0.000902	CcSEcCtD
Nabumetone—Pruritus—Fluorouracil—pancreatic cancer	0.000202	0.000898	CcSEcCtD
Nabumetone—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000202	0.000897	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—PIK3CD—pancreatic cancer	0.000202	0.0142	CbGpPWpGaD
Nabumetone—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.0002	0.000889	CcSEcCtD
Nabumetone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000199	0.000884	CcSEcCtD
Nabumetone—Renal failure—Doxorubicin—pancreatic cancer	0.000199	0.000882	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—KDR—pancreatic cancer	0.000198	0.0139	CbGpPWpGaD
Nabumetone—Dizziness—Irinotecan—pancreatic cancer	0.000197	0.000877	CcSEcCtD
Nabumetone—Haemoglobin—Epirubicin—pancreatic cancer	0.000197	0.000875	CcSEcCtD
Nabumetone—Stomatitis—Doxorubicin—pancreatic cancer	0.000197	0.000874	CcSEcCtD
Nabumetone—Jaundice—Doxorubicin—pancreatic cancer	0.000197	0.000874	CcSEcCtD
Nabumetone—Anorexia—Docetaxel—pancreatic cancer	0.000197	0.000874	CcSEcCtD
Nabumetone—Haemorrhage—Epirubicin—pancreatic cancer	0.000196	0.00087	CcSEcCtD
Nabumetone—Diarrhoea—Fluorouracil—pancreatic cancer	0.000196	0.000869	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—STAT3—pancreatic cancer	0.000195	0.0137	CbGpPWpGaD
Nabumetone—Haematuria—Doxorubicin—pancreatic cancer	0.000193	0.000855	CcSEcCtD
Nabumetone—Vomiting—Irinotecan—pancreatic cancer	0.00019	0.000843	CcSEcCtD
Nabumetone—Dizziness—Fluorouracil—pancreatic cancer	0.000189	0.00084	CcSEcCtD
Nabumetone—Visual impairment—Epirubicin—pancreatic cancer	0.000189	0.000839	CcSEcCtD
Nabumetone—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000189	0.000837	CcSEcCtD
Nabumetone—Rash—Irinotecan—pancreatic cancer	0.000188	0.000836	CcSEcCtD
Nabumetone—Dermatitis—Irinotecan—pancreatic cancer	0.000188	0.000835	CcSEcCtD
Nabumetone—Headache—Irinotecan—pancreatic cancer	0.000187	0.000831	CcSEcCtD
Nabumetone—Insomnia—Docetaxel—pancreatic cancer	0.000187	0.000829	CcSEcCtD
Nabumetone—Paraesthesia—Docetaxel—pancreatic cancer	0.000185	0.000823	CcSEcCtD
Nabumetone—Erythema multiforme—Epirubicin—pancreatic cancer	0.000185	0.000823	CcSEcCtD
Nabumetone—Vomiting—Gemcitabine—pancreatic cancer	0.000185	0.000821	CcSEcCtD
Nabumetone—Dyspnoea—Docetaxel—pancreatic cancer	0.000184	0.000817	CcSEcCtD
Nabumetone—Somnolence—Docetaxel—pancreatic cancer	0.000184	0.000815	CcSEcCtD
Nabumetone—Rash—Gemcitabine—pancreatic cancer	0.000183	0.000814	CcSEcCtD
Nabumetone—Dermatitis—Gemcitabine—pancreatic cancer	0.000183	0.000814	CcSEcCtD
Nabumetone—Tinnitus—Epirubicin—pancreatic cancer	0.000183	0.000811	CcSEcCtD
Nabumetone—Haemoglobin—Doxorubicin—pancreatic cancer	0.000182	0.000809	CcSEcCtD
Nabumetone—Headache—Gemcitabine—pancreatic cancer	0.000182	0.000809	CcSEcCtD
Nabumetone—Vomiting—Fluorouracil—pancreatic cancer	0.000182	0.000807	CcSEcCtD
Nabumetone—Dyspepsia—Docetaxel—pancreatic cancer	0.000182	0.000807	CcSEcCtD
Nabumetone—Haemorrhage—Doxorubicin—pancreatic cancer	0.000181	0.000805	CcSEcCtD
Nabumetone—Rash—Fluorouracil—pancreatic cancer	0.00018	0.000801	CcSEcCtD
Nabumetone—Dermatitis—Fluorouracil—pancreatic cancer	0.00018	0.0008	CcSEcCtD
Nabumetone—Decreased appetite—Docetaxel—pancreatic cancer	0.000179	0.000797	CcSEcCtD
Nabumetone—Headache—Fluorouracil—pancreatic cancer	0.000179	0.000795	CcSEcCtD
Nabumetone—Fatigue—Docetaxel—pancreatic cancer	0.000178	0.00079	CcSEcCtD
Nabumetone—Nausea—Irinotecan—pancreatic cancer	0.000177	0.000788	CcSEcCtD
Nabumetone—Constipation—Docetaxel—pancreatic cancer	0.000177	0.000784	CcSEcCtD
Nabumetone—Chills—Epirubicin—pancreatic cancer	0.000176	0.000781	CcSEcCtD
Nabumetone—Arrhythmia—Epirubicin—pancreatic cancer	0.000175	0.000777	CcSEcCtD
Nabumetone—Visual impairment—Doxorubicin—pancreatic cancer	0.000175	0.000776	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—PTGS2—pancreatic cancer	0.000174	0.0122	CbGpPWpGaD
Nabumetone—Alopecia—Epirubicin—pancreatic cancer	0.000173	0.000769	CcSEcCtD
Nabumetone—Nausea—Gemcitabine—pancreatic cancer	0.000173	0.000767	CcSEcCtD
Nabumetone—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000171	0.000761	CcSEcCtD
Nabumetone—Feeling abnormal—Docetaxel—pancreatic cancer	0.00017	0.000755	CcSEcCtD
Nabumetone—Nausea—Fluorouracil—pancreatic cancer	0.00017	0.000754	CcSEcCtD
Nabumetone—Tinnitus—Doxorubicin—pancreatic cancer	0.000169	0.000751	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—CXCL8—pancreatic cancer	0.000169	0.0119	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000169	0.000749	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—TNF—pancreatic cancer	0.000169	0.0118	CbGpPWpGaD
Nabumetone—Flatulence—Epirubicin—pancreatic cancer	0.000168	0.000746	CcSEcCtD
Nabumetone—Tension—Epirubicin—pancreatic cancer	0.000167	0.000743	CcSEcCtD
Nabumetone—Nervousness—Epirubicin—pancreatic cancer	0.000166	0.000736	CcSEcCtD
Nabumetone—Abdominal pain—Docetaxel—pancreatic cancer	0.000163	0.000725	CcSEcCtD
Nabumetone—Body temperature increased—Docetaxel—pancreatic cancer	0.000163	0.000725	CcSEcCtD
Nabumetone—Chills—Doxorubicin—pancreatic cancer	0.000163	0.000722	CcSEcCtD
Nabumetone—Arrhythmia—Doxorubicin—pancreatic cancer	0.000162	0.000719	CcSEcCtD
Nabumetone—Alopecia—Doxorubicin—pancreatic cancer	0.00016	0.000711	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—PIK3CD—pancreatic cancer	0.00016	0.0112	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000158	0.000703	CcSEcCtD
Nabumetone—Anaemia—Epirubicin—pancreatic cancer	0.000158	0.0007	CcSEcCtD
Nabumetone—Agitation—Epirubicin—pancreatic cancer	0.000157	0.000696	CcSEcCtD
Nabumetone—Flatulence—Doxorubicin—pancreatic cancer	0.000156	0.000691	CcSEcCtD
Nabumetone—Tension—Doxorubicin—pancreatic cancer	0.000155	0.000688	CcSEcCtD
Nabumetone—Malaise—Epirubicin—pancreatic cancer	0.000154	0.000683	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—PIK3CA—pancreatic cancer	0.000154	0.0108	CbGpPWpGaD
Nabumetone—Nervousness—Doxorubicin—pancreatic cancer	0.000153	0.000681	CcSEcCtD
Nabumetone—Vertigo—Epirubicin—pancreatic cancer	0.000153	0.000681	CcSEcCtD
Nabumetone—Syncope—Epirubicin—pancreatic cancer	0.000153	0.000679	CcSEcCtD
Nabumetone—Leukopenia—Epirubicin—pancreatic cancer	0.000153	0.000678	CcSEcCtD
Nabumetone—Hypersensitivity—Docetaxel—pancreatic cancer	0.000152	0.000675	CcSEcCtD
Nabumetone—Palpitations—Epirubicin—pancreatic cancer	0.000151	0.000669	CcSEcCtD
Nabumetone—Loss of consciousness—Epirubicin—pancreatic cancer	0.00015	0.000666	CcSEcCtD
Nabumetone—Cough—Epirubicin—pancreatic cancer	0.000149	0.000661	CcSEcCtD
Nabumetone—Asthenia—Docetaxel—pancreatic cancer	0.000148	0.000658	CcSEcCtD
Nabumetone—Hypertension—Epirubicin—pancreatic cancer	0.000147	0.000654	CcSEcCtD
Nabumetone—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000146	0.00065	CcSEcCtD
Nabumetone—Pruritus—Docetaxel—pancreatic cancer	0.000146	0.000648	CcSEcCtD
Nabumetone—Anaemia—Doxorubicin—pancreatic cancer	0.000146	0.000648	CcSEcCtD
Nabumetone—Agitation—Doxorubicin—pancreatic cancer	0.000145	0.000644	CcSEcCtD
Nabumetone—Anxiety—Epirubicin—pancreatic cancer	0.000145	0.000643	CcSEcCtD
Nabumetone—PTGS1—Eicosanoid Synthesis—PTGS2—pancreatic cancer	0.000145	0.0101	CbGpPWpGaD
Nabumetone—Discomfort—Epirubicin—pancreatic cancer	0.000144	0.000637	CcSEcCtD
Nabumetone—Malaise—Doxorubicin—pancreatic cancer	0.000142	0.000632	CcSEcCtD
Nabumetone—Dry mouth—Epirubicin—pancreatic cancer	0.000142	0.000631	CcSEcCtD
Nabumetone—Vertigo—Doxorubicin—pancreatic cancer	0.000142	0.00063	CcSEcCtD
Nabumetone—Syncope—Doxorubicin—pancreatic cancer	0.000142	0.000629	CcSEcCtD
Nabumetone—Leukopenia—Doxorubicin—pancreatic cancer	0.000141	0.000627	CcSEcCtD
Nabumetone—Diarrhoea—Docetaxel—pancreatic cancer	0.000141	0.000627	CcSEcCtD
Nabumetone—Confusional state—Epirubicin—pancreatic cancer	0.00014	0.000623	CcSEcCtD
Nabumetone—Palpitations—Doxorubicin—pancreatic cancer	0.00014	0.000619	CcSEcCtD
Nabumetone—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000139	0.000618	CcSEcCtD
Nabumetone—Oedema—Epirubicin—pancreatic cancer	0.000139	0.000618	CcSEcCtD
Nabumetone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000139	0.000616	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CDKN2A—pancreatic cancer	0.000139	0.00973	CbGpPWpGaD
Nabumetone—Cough—Doxorubicin—pancreatic cancer	0.000138	0.000612	CcSEcCtD
Nabumetone—Shock—Epirubicin—pancreatic cancer	0.000137	0.000608	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TFF1—pancreatic cancer	0.000137	0.00958	CbGpPWpGaD
Nabumetone—Dizziness—Docetaxel—pancreatic cancer	0.000137	0.000606	CcSEcCtD
Nabumetone—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000136	0.000605	CcSEcCtD
Nabumetone—Hypertension—Doxorubicin—pancreatic cancer	0.000136	0.000605	CcSEcCtD
Nabumetone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000135	0.000598	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—CXCL8—pancreatic cancer	0.000134	0.00941	CbGpPWpGaD
Nabumetone—Anxiety—Doxorubicin—pancreatic cancer	0.000134	0.000595	CcSEcCtD
Nabumetone—Discomfort—Doxorubicin—pancreatic cancer	0.000133	0.00059	CcSEcCtD
Nabumetone—Anorexia—Epirubicin—pancreatic cancer	0.000133	0.000589	CcSEcCtD
Nabumetone—Dry mouth—Doxorubicin—pancreatic cancer	0.000131	0.000584	CcSEcCtD
Nabumetone—Vomiting—Docetaxel—pancreatic cancer	0.000131	0.000583	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—TNF—pancreatic cancer	0.000131	0.00915	CbGpPWpGaD
Nabumetone—Rash—Docetaxel—pancreatic cancer	0.00013	0.000578	CcSEcCtD
Nabumetone—Dermatitis—Docetaxel—pancreatic cancer	0.00013	0.000577	CcSEcCtD
Nabumetone—Confusional state—Doxorubicin—pancreatic cancer	0.00013	0.000577	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—PTGS2—pancreatic cancer	0.00013	0.00909	CbGpPWpGaD
Nabumetone—Headache—Docetaxel—pancreatic cancer	0.000129	0.000574	CcSEcCtD
Nabumetone—Oedema—Doxorubicin—pancreatic cancer	0.000129	0.000572	CcSEcCtD
Nabumetone—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000129	0.000572	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—AHR—pancreatic cancer	0.000127	0.00889	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—pancreatic cancer	0.000127	0.00889	CbGpPWpGaD
Nabumetone—Shock—Doxorubicin—pancreatic cancer	0.000127	0.000563	CcSEcCtD
Nabumetone—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000126	0.00056	CcSEcCtD
Nabumetone—Insomnia—Epirubicin—pancreatic cancer	0.000126	0.000559	CcSEcCtD
Nabumetone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—pancreatic cancer	0.000125	0.00877	CbGpPWpGaD
Nabumetone—Paraesthesia—Epirubicin—pancreatic cancer	0.000125	0.000555	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—PTGS2—pancreatic cancer	0.000125	0.00876	CbGpPWpGaD
Nabumetone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000125	0.000553	CcSEcCtD
Nabumetone—Dyspnoea—Epirubicin—pancreatic cancer	0.000124	0.000551	CcSEcCtD
Nabumetone—Somnolence—Epirubicin—pancreatic cancer	0.000124	0.00055	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—pancreatic cancer	0.000124	0.00866	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—pancreatic cancer	0.000124	0.00866	CbGpPWpGaD
Nabumetone—Anorexia—Doxorubicin—pancreatic cancer	0.000123	0.000545	CcSEcCtD
Nabumetone—Nausea—Docetaxel—pancreatic cancer	0.000123	0.000544	CcSEcCtD
Nabumetone—Dyspepsia—Epirubicin—pancreatic cancer	0.000123	0.000544	CcSEcCtD
Nabumetone—Decreased appetite—Epirubicin—pancreatic cancer	0.000121	0.000537	CcSEcCtD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—pancreatic cancer	0.000121	0.00848	CbGpPWpGaD
Nabumetone—Fatigue—Epirubicin—pancreatic cancer	0.00012	0.000533	CcSEcCtD
Nabumetone—Constipation—Epirubicin—pancreatic cancer	0.000119	0.000529	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—TNF—pancreatic cancer	0.000118	0.00825	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—CCND1—pancreatic cancer	0.000117	0.00822	CbGpPWpGaD
Nabumetone—Insomnia—Doxorubicin—pancreatic cancer	0.000117	0.000517	CcSEcCtD
Nabumetone—Paraesthesia—Doxorubicin—pancreatic cancer	0.000116	0.000514	CcSEcCtD
Nabumetone—Dyspnoea—Doxorubicin—pancreatic cancer	0.000115	0.00051	CcSEcCtD
Nabumetone—Feeling abnormal—Epirubicin—pancreatic cancer	0.000115	0.000509	CcSEcCtD
Nabumetone—Somnolence—Doxorubicin—pancreatic cancer	0.000115	0.000509	CcSEcCtD
Nabumetone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000114	0.000506	CcSEcCtD
Nabumetone—Dyspepsia—Doxorubicin—pancreatic cancer	0.000113	0.000503	CcSEcCtD
Nabumetone—Decreased appetite—Doxorubicin—pancreatic cancer	0.000112	0.000497	CcSEcCtD
Nabumetone—Fatigue—Doxorubicin—pancreatic cancer	0.000111	0.000493	CcSEcCtD
Nabumetone—Urticaria—Epirubicin—pancreatic cancer	0.000111	0.000491	CcSEcCtD
Nabumetone—Constipation—Doxorubicin—pancreatic cancer	0.00011	0.000489	CcSEcCtD
Nabumetone—Body temperature increased—Epirubicin—pancreatic cancer	0.00011	0.000489	CcSEcCtD
Nabumetone—Abdominal pain—Epirubicin—pancreatic cancer	0.00011	0.000489	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—VEGFA—pancreatic cancer	0.000109	0.00764	CbGpPWpGaD
Nabumetone—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000106	0.000471	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TNF—pancreatic cancer	0.000106	0.00745	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000105	0.000468	CcSEcCtD
Nabumetone—Hypersensitivity—Epirubicin—pancreatic cancer	0.000103	0.000455	CcSEcCtD
Nabumetone—Urticaria—Doxorubicin—pancreatic cancer	0.000102	0.000454	CcSEcCtD
Nabumetone—Abdominal pain—Doxorubicin—pancreatic cancer	0.000102	0.000452	CcSEcCtD
Nabumetone—Body temperature increased—Doxorubicin—pancreatic cancer	0.000102	0.000452	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—NRAS—pancreatic cancer	0.000101	0.00708	CbGpPWpGaD
Nabumetone—Asthenia—Epirubicin—pancreatic cancer	9.99e-05	0.000444	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—DAXX—pancreatic cancer	9.92e-05	0.00696	CbGpPWpGaD
Nabumetone—Pruritus—Epirubicin—pancreatic cancer	9.85e-05	0.000437	CcSEcCtD
Nabumetone—Diarrhoea—Epirubicin—pancreatic cancer	9.53e-05	0.000423	CcSEcCtD
Nabumetone—Hypersensitivity—Doxorubicin—pancreatic cancer	9.49e-05	0.000421	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—MYC—pancreatic cancer	9.4e-05	0.00659	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—TP53—pancreatic cancer	9.36e-05	0.00656	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—TNF—pancreatic cancer	9.34e-05	0.00655	CbGpPWpGaD
Nabumetone—Asthenia—Doxorubicin—pancreatic cancer	9.24e-05	0.00041	CcSEcCtD
Nabumetone—Dizziness—Epirubicin—pancreatic cancer	9.21e-05	0.000409	CcSEcCtD
Nabumetone—Pruritus—Doxorubicin—pancreatic cancer	9.12e-05	0.000405	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—SOD2—pancreatic cancer	9.1e-05	0.00638	CbGpPWpGaD
Nabumetone—Vomiting—Epirubicin—pancreatic cancer	8.85e-05	0.000393	CcSEcCtD
Nabumetone—Diarrhoea—Doxorubicin—pancreatic cancer	8.82e-05	0.000391	CcSEcCtD
Nabumetone—Rash—Epirubicin—pancreatic cancer	8.78e-05	0.00039	CcSEcCtD
Nabumetone—Dermatitis—Epirubicin—pancreatic cancer	8.77e-05	0.000389	CcSEcCtD
Nabumetone—Headache—Epirubicin—pancreatic cancer	8.72e-05	0.000387	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—KRAS—pancreatic cancer	8.68e-05	0.00609	CbGpPWpGaD
Nabumetone—Dizziness—Doxorubicin—pancreatic cancer	8.52e-05	0.000378	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—TNF—pancreatic cancer	8.44e-05	0.00592	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	8.3e-05	0.00582	CbGpPWpGaD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—STAT3—pancreatic cancer	8.27e-05	0.0058	CbGpPWpGaD
Nabumetone—Nausea—Epirubicin—pancreatic cancer	8.27e-05	0.000367	CcSEcCtD
Nabumetone—Vomiting—Doxorubicin—pancreatic cancer	8.19e-05	0.000364	CcSEcCtD
Nabumetone—CYP1A2—Melatonin metabolism and effects—APOE—pancreatic cancer	8.15e-05	0.00571	CbGpPWpGaD
Nabumetone—Rash—Doxorubicin—pancreatic cancer	8.12e-05	0.000361	CcSEcCtD
Nabumetone—Dermatitis—Doxorubicin—pancreatic cancer	8.12e-05	0.00036	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—pancreatic cancer	8.11e-05	0.00569	CbGpPWpGaD
Nabumetone—Headache—Doxorubicin—pancreatic cancer	8.07e-05	0.000358	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—PTGS2—pancreatic cancer	8.04e-05	0.00564	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—GADD45A—pancreatic cancer	7.82e-05	0.00548	CbGpPWpGaD
Nabumetone—Nausea—Doxorubicin—pancreatic cancer	7.65e-05	0.00034	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—HES1—pancreatic cancer	7.52e-05	0.00527	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—HRAS—pancreatic cancer	7.38e-05	0.00518	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—SOD2—pancreatic cancer	7.23e-05	0.00507	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—pancreatic cancer	6.99e-05	0.0049	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	6.89e-05	0.00483	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	6.27e-05	0.0044	CbGpPWpGaD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	6.25e-05	0.00438	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	6.19e-05	0.00434	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—pancreatic cancer	6.19e-05	0.00434	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—pancreatic cancer	5.92e-05	0.00415	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	5.52e-05	0.00387	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	5.41e-05	0.0038	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	5.37e-05	0.00377	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	5.32e-05	0.00373	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	5.31e-05	0.00372	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—PTGS2—pancreatic cancer	5.11e-05	0.00359	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—pancreatic cancer	5.05e-05	0.00354	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	4.94e-05	0.00347	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	4.83e-05	0.00339	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	4.7e-05	0.00329	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	4.6e-05	0.00323	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	4.57e-05	0.0032	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	4.56e-05	0.00319	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CDKN2A—pancreatic cancer	4.51e-05	0.00316	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—pancreatic cancer	4.31e-05	0.00302	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	4.12e-05	0.00289	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	3.99e-05	0.0028	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	3.92e-05	0.00275	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—RB1—pancreatic cancer	3.91e-05	0.00274	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	3.88e-05	0.00272	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—pancreatic cancer	3.86e-05	0.00271	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CCND1—pancreatic cancer	3.81e-05	0.00267	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—PTGS2—pancreatic cancer	3.61e-05	0.00253	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—TNF—pancreatic cancer	3.45e-05	0.00242	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—NRAS—pancreatic cancer	3.28e-05	0.0023	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	3.12e-05	0.00219	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	3.12e-05	0.00219	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CXCL8—pancreatic cancer	3.11e-05	0.00218	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—MYC—pancreatic cancer	3.05e-05	0.00214	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	3.04e-05	0.00213	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	3e-05	0.00211	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CASP3—pancreatic cancer	2.98e-05	0.00209	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	2.97e-05	0.00208	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CCND1—pancreatic cancer	2.9e-05	0.00203	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	2.84e-05	0.00199	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—KRAS—pancreatic cancer	2.82e-05	0.00198	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MMP9—pancreatic cancer	2.82e-05	0.00197	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	2.8e-05	0.00196	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	2.79e-05	0.00196	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—TNF—pancreatic cancer	2.74e-05	0.00192	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	2.74e-05	0.00192	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	2.74e-05	0.00192	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PRSS1—pancreatic cancer	2.68e-05	0.00188	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	2.61e-05	0.00183	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	2.61e-05	0.00183	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	2.58e-05	0.00181	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ZNRF3—pancreatic cancer	2.54e-05	0.00178	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PRSS1—pancreatic cancer	2.54e-05	0.00178	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—HRAS—pancreatic cancer	2.4e-05	0.00168	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MYC—pancreatic cancer	2.33e-05	0.00163	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ARG2—pancreatic cancer	2.32e-05	0.00163	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TGFB1—pancreatic cancer	2.32e-05	0.00163	CbGpPWpGaD
Nabumetone—PTGS2—Disease—DTX1—pancreatic cancer	2.3e-05	0.00161	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—EGFR—pancreatic cancer	2.28e-05	0.0016	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	2.2e-05	0.00154	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TNF—pancreatic cancer	2.17e-05	0.00152	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PRSS1—pancreatic cancer	2.13e-05	0.00149	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TYMP—pancreatic cancer	2.03e-05	0.00142	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	2.03e-05	0.00142	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	1.97e-05	0.00138	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	1.95e-05	0.00137	CbGpPWpGaD
Nabumetone—PTGS2—Disease—DTX4—pancreatic cancer	1.93e-05	0.00135	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—pancreatic cancer	1.91e-05	0.00134	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	1.9e-05	0.00134	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PPP2R5B—pancreatic cancer	1.87e-05	0.00131	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ARG2—pancreatic cancer	1.85e-05	0.00129	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HEY2—pancreatic cancer	1.8e-05	0.00126	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	1.77e-05	0.00124	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	1.72e-05	0.00121	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.68e-05	0.00118	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HEY1—pancreatic cancer	1.67e-05	0.00117	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GLP1R—pancreatic cancer	1.64e-05	0.00115	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TYMP—pancreatic cancer	1.61e-05	0.00113	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—DPYD—pancreatic cancer	1.61e-05	0.00113	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	1.58e-05	0.00111	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	1.58e-05	0.00111	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	1.55e-05	0.00109	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC2A2—pancreatic cancer	1.53e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.51e-05	0.00106	CbGpPWpGaD
Nabumetone—PTGS2—Disease—JAG2—pancreatic cancer	1.48e-05	0.00104	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	1.47e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	1.46e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.46e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MEN1—pancreatic cancer	1.46e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SLC2A2—pancreatic cancer	1.45e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SHH—pancreatic cancer	1.39e-05	0.000976	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IAPP—pancreatic cancer	1.37e-05	0.000964	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.34e-05	0.000942	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.33e-05	0.000933	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.33e-05	0.000933	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HSPA1B—pancreatic cancer	1.32e-05	0.000926	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GLP1R—pancreatic cancer	1.3e-05	0.000912	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.3e-05	0.000911	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—DPYD—pancreatic cancer	1.28e-05	0.000897	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC2A2—pancreatic cancer	1.21e-05	0.000851	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PRSS1—pancreatic cancer	1.2e-05	0.000844	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.2e-05	0.000842	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CD44—pancreatic cancer	1.18e-05	0.00083	CbGpPWpGaD
Nabumetone—PTGS2—Disease—JAG1—pancreatic cancer	1.18e-05	0.000828	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.16e-05	0.000813	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.16e-05	0.000813	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.15e-05	0.000806	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GCG—pancreatic cancer	1.14e-05	0.000796	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CD44—pancreatic cancer	1.12e-05	0.000787	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HSPA1A—pancreatic cancer	1.11e-05	0.000781	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.1e-05	0.00077	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—STK11—pancreatic cancer	1.07e-05	0.000748	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.06e-05	0.00074	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.04e-05	0.000732	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1e-05	0.000702	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CD44—pancreatic cancer	9.4e-06	0.000659	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.2e-06	0.000645	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TYMS—pancreatic cancer	9.18e-06	0.000644	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TYMP—pancreatic cancer	9.13e-06	0.00064	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GCG—pancreatic cancer	9.01e-06	0.000632	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SMAD4—pancreatic cancer	8.86e-06	0.000621	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HES1—pancreatic cancer	8.65e-06	0.000607	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—STK11—pancreatic cancer	8.47e-06	0.000594	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.95e-06	0.000558	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TERT—pancreatic cancer	7.58e-06	0.000532	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.53e-06	0.000528	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—APOE—pancreatic cancer	7.47e-06	0.000524	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GLP1R—pancreatic cancer	7.36e-06	0.000516	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TYMS—pancreatic cancer	7.29e-06	0.000511	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HIF1A—pancreatic cancer	7.25e-06	0.000508	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—DPYD—pancreatic cancer	7.24e-06	0.000508	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TSC2—pancreatic cancer	7.23e-06	0.000507	CbGpPWpGaD
Nabumetone—PTGS2—Disease—APOE—pancreatic cancer	7.08e-06	0.000496	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.07e-06	0.000496	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	6.87e-06	0.000482	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.8e-06	0.000477	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CG—pancreatic cancer	6.74e-06	0.000472	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.56e-06	0.00046	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NOTCH1—pancreatic cancer	6.53e-06	0.000458	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PPARG—pancreatic cancer	6.5e-06	0.000456	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGF—pancreatic cancer	6.31e-06	0.000443	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	5.97e-06	0.000419	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—APOE—pancreatic cancer	5.93e-06	0.000416	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CD—pancreatic cancer	5.92e-06	0.000415	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CD—pancreatic cancer	5.61e-06	0.000394	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.61e-06	0.000393	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CG—pancreatic cancer	5.35e-06	0.000375	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CD44—pancreatic cancer	5.32e-06	0.000373	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.21e-06	0.000365	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CB—pancreatic cancer	5.16e-06	0.000362	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PPARG—pancreatic cancer	5.16e-06	0.000362	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.16e-06	0.000362	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTGS2—pancreatic cancer	5.12e-06	0.000359	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GCG—pancreatic cancer	5.1e-06	0.000358	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CB—pancreatic cancer	4.89e-06	0.000343	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—STK11—pancreatic cancer	4.79e-06	0.000336	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CD—pancreatic cancer	4.7e-06	0.00033	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.5e-06	0.000316	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTEN—pancreatic cancer	4.46e-06	0.000313	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CTNNB1—pancreatic cancer	4.34e-06	0.000304	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PTEN—pancreatic cancer	4.23e-06	0.000297	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TYMS—pancreatic cancer	4.12e-06	0.000289	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CB—pancreatic cancer	4.1e-06	0.000287	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SRC—pancreatic cancer	3.92e-06	0.000275	CbGpPWpGaD
Nabumetone—PTGS2—Disease—STAT3—pancreatic cancer	3.78e-06	0.000265	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NRAS—pancreatic cancer	3.77e-06	0.000265	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTEN—pancreatic cancer	3.54e-06	0.000248	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MYC—pancreatic cancer	3.51e-06	0.000246	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFB1—pancreatic cancer	3.51e-06	0.000246	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGFR—pancreatic cancer	3.44e-06	0.000241	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—APOE—pancreatic cancer	3.35e-06	0.000235	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KRAS—pancreatic cancer	3.25e-06	0.000228	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.17e-06	0.000223	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PIK3CA—pancreatic cancer	3.15e-06	0.000221	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.03e-06	0.000212	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PIK3CA—pancreatic cancer	2.98e-06	0.000209	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PPARG—pancreatic cancer	2.92e-06	0.000205	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HRAS—pancreatic cancer	2.76e-06	0.000194	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.66e-06	0.000187	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—AKT1—pancreatic cancer	2.57e-06	0.00018	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PIK3CA—pancreatic cancer	2.5e-06	0.000175	CbGpPWpGaD
Nabumetone—PTGS2—Disease—AKT1—pancreatic cancer	2.44e-06	0.000171	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.32e-06	0.000163	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.3e-06	0.000161	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—AKT1—pancreatic cancer	2.04e-06	0.000143	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTEN—pancreatic cancer	2e-06	0.000141	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.41e-06	9.91e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.16e-06	8.1e-05	CbGpPWpGaD
